Literature DB >> 21935299

Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.

Emily Knapp, Kristin Watson.   

Abstract

Entities:  

Year:  2011        PMID： 21935299      PMCID： PMC3171823     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  45 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

3.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

Authors:  Dagmar Kubitza; Michael Becka; Georg Wensing; Barbara Voith; Michael Zuehlsdorf
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

4.  The mechanism of atrial antiarrhythmic action of RSD1235.

Authors:  David Fedida; Peter M R Orth; Janet Y C Chen; Shunping Lin; Bertrand Plouvier; Grace Jung; Alan M Ezrin; Gregory N Beatch
Journal:  J Cardiovasc Electrophysiol       Date:  2005-11

5.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.

Authors:  Peter R Kowey; Paul Dorian; L Brent Mitchell; Craig M Pratt; Denis Roy; Peter J Schwartz; Jerzy Sadowski; Dorota Sobczyk; Andrzej Bochenek; Egon Toft
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12

7.  Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Authors:  John H Alexander; Richard C Becker; Deepak L Bhatt; Frank Cools; Filippo Crea; Mikael Dellborg; Keith A A Fox; Shaun G Goodman; Robert A Harrington; Kurt Huber; Steen Husted; Basil S Lewis; Jose Lopez-Sendon; Puneet Mohan; Gilles Montalescot; Mikhail Ruda; Witold Ruzyllo; Freek Verheugt; Lars Wallentin
Journal:  Circulation       Date:  2009-05-26       Impact factor: 29.690

8.  Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.

Authors:  Thibaud Damy; Françoise Pousset; Henri Caplain; Jean-Sébastien Hulot; Philippe Lechat
Journal:  Fundam Clin Pharmacol       Date:  2004-02       Impact factor: 2.748

9.  Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.

Authors:  Dagmar Kubitza; Michael Becka; Angelika Roth; Wolfgang Mueck
Journal:  Curr Med Res Opin       Date:  2008-08-19       Impact factor: 2.580

10.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Janice Pogue; Robert G Hart; Stefan H Hohnloser; Marc Pfeffer; Susan Chrolavicius; Salim Yusuf
Journal:  N Engl J Med       Date:  2009-03-31       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.